Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ44589

Comparative study of cardio protective effect between enalapril and dexrazoxane against doxorubicin induce toxicity

Ruaa Allawy Hasan, Dr. Intesar Tarik Numan, Dr. Nadiah Hameed Mohamed

Abstract

Doxorubicin (DOX)is one of the anthracycline family. It is a highly effective anticancer drug. Several studies focused on the role of DOX in anticancer activities, but the cardiotoxicity is the most dangerous side effect. The experimental-based finding on heart injury reduced by dexrazoxane(DXZ) treatment. DXZ is a first-line drug for the treatment of iron poisoning, which is a chelating agent considered as an antidot for DOX cardiotoxicity, and also enalapril, which is an angiotensin converting enzyme (ACE) inhibitor used to reduce cardiotoxicity. In the present study, 48 male rats were included. The DXZ was given in a dose of 200mg/kg intraperitoneal (IP) three times weekly for seven days. And compare with enalopril given at a dose of 2 mg/kg administered orally via oral gavage for 7 days. On day 7, DOX at a dose of 20 mg/kg IP was administered. At the end of the experiment, biomarkers such as troponin-I(TNI) and glutathione(GSH) were measured. Necrosis on cardiac tissue was also measured. As a result, coadministration of enalapril with DOX and the coadministration of DXZ with DOX reduced the DOX cardiotoxicity but in different ways. Finally, campers the cardioprotective effect of enalapril and DXZ against DOX cardiotoxicity. In conclusion, DXZ was seen as more effective than enalapril against DOX cardiotoxicity. Since DXZ produces dangerous side effects in the same case, enalapril can be used instead of it.

Keywords

doxorubicin, dexrazoxane, cardiotoxicity, cardioprotective, enalopril.

Full Text

PDF

References

?>